Public perception of the resumption of HPV vaccine recommendation in Japan
Twitter content analysis
Datos Bibliográficos
| ID | 22943744 |
|---|---|
| Autores | Marina Terada (0000-0002-6087-1807, The University of Tokyo), Tsuyoshi Okuhara (0000-0002-6251-3587, The University of Tokyo), Tomomi Nagasawa (0000-0002-7757-2985, The University of Tokyo), Hiroko Okada (0000-0001-7877-9753, The University of Tokyo), Eiko Goto (0000-0001-8288-7343, The University of Tokyo), Takahiro Kiuchi (0000-0001-5934-0681, The University of Tokyo) |
| Año | 2023 |
| Volumen | 38 |
| Número | 6 |
| Fecha de publicación | 2023-12-01 |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | Health Promotion International (JOURNAL) |
| Identificadores de la revista | ISSN: 0957-4824 • E-ISSN: 1460-2245 |
| Editorial | Oxford University Press (OUP) (PUBLISHER) |
| DOI | 10.1093/heapro/daad153 |
| PMID | 37966160 |
| OpenAlex | W4388706802 |
| Idioma | EN |
| Citas recibidas | 1 |
| Referencias citadas | 43 |
On 12 November 2021, after a stagnation of 8.5 years, Japan decided to resume proactive recommendations for HPV vaccines. However, it is not known how the public reacted to the resumption of proactive recommendations for HPV vaccines, which are key elements in health communication that promote HPV vaccination. This study aimed to capture discussions on HPV vaccination on Twitter and to identify user characteristics, sentiments, discussed themes and their potential reach before and after 12 November 2021, when the Ministry of Health, Labour, and Welfare’s decision to resume proactive recommendation for HPV vaccines was first reported by the media in Japan. This study conducted a content analysis of tweets related to HPV vaccines posted on 11 November and 12 November 2021. Tweets were coded in terms of user characteristics, sentiments (i.e. positive, negative and neutral) and themes. Reach was measured by the number of retweets, likes and followers. A total of 3623 tweets were identified. The results showed that approximately 50% of health professionals and researchers tweeted neutral content about HPV vaccines. The most frequently discussed theme was the safety and side effects of HPV vaccines, which was accompanied by mainly negative sentiments. Although health professionals and researchers are influential on Twitter, half of them tweeted neutrally about HPV vaccines. Influential professionals, such as health professionals and researchers, are expected to disseminate accurate information to correct misinformation and recommend HPV vaccination on Twitter to overcome the HPV vaccination crisis, which is characterized by the low vaccination rates.
Cancer · Cervical cancer · Christian ministry · Content analysis · Family medicine · Health care · Health professionals · HPV infection · HPV vaccines · Misinformation · Perception · Political science · Public relations · Social media · Sociology · Vaccination · Cervical Cancer and HPV Research · Medicine · Misinformation and Its Impacts · Psychology · Vaccine Coverage and Hesitancy · Virology
Social media and vaccine hesitancy
Content Analysis
Computing inter‐rater reliability and its variance in the presence of high agreement
A comparison of Cohen’s Kappa and Gwet’s AC1 when calculating inter-rater reliability coefficients
HPV vaccination introduction worldwide and WHO and Unicef estimates of national HPV immunization coverage 2010–2019
Worldwide burden of cancer attributable to HPV by site, country and HPV type
Barriers to Human Papillomavirus Vaccination Among US Adolescents
Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake
Prevalence of HPV Infection Among Females in the United States
Debates about vaccines and climate change on social media networks
Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation
Newspaper coverage before and after the HPV vaccination crisis began in Japan
Twitter as a Tool for Health Research
| Citas por año | 1 |
|---|---|
| Intervalo de citas | 2026 - 2026 (1) |
| Altamente citado | No |